Christopher W Campbell

US Patent:

20100144653, Jun 10, 2010

Filed:

May 24, 2006

Appl. No.:

11/920909

Inventors:

Kevin J. Yarema - Woodstock MD, US
Mark B. Jones - Baltimore NY, US
Christopher T. Campbell - Baltimore MD, US
Udayanath Aich - Baltimore MD, US

Assignee:

The Johns Hopkins University - Baltimore MD

International Classification:

A61K 31/7028
C07H 15/12
A61P 35/00
A61P 1/00
A61P 19/02
A61P 9/10
A61P 37/06
A61P 25/16
A61P 25/14
A61P 1/04

US Classification:

514 25, 536 172

Abstract:

Described herein are fatty acid carbohydrate hybrid compounds and derivatives thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions thereof.

US Patent:

20110206734, Aug 25, 2011

Filed:

Aug 7, 2008

Appl. No.:

12/671994

Inventors:

Kevin J. Yarema - Woodstock MD, US
Udayanath Aich - Baltimore MD, US
Christopher Thomas Campbell - Baltimore MD, US
Srinivasa-Gopalan Sampathkumar - New Delhi, IN
Sean S. Choi - Baltimore MD, US
Michael Adam Meledeo - Odenton MD, US
Christopher Weier - Baltimore MD, US

Assignee:

THE JOHNS HOPKINS UNIVERSITY - Baltimore MD

International Classification:

A61K 39/00
C07H 15/04
A61K 31/7028
C07H 13/04
A61K 31/7024
A61P 35/00
C12N 5/071

US Classification:

4242771, 536 182, 514 25, 536 53, 514 62, 435375

Abstract:

Described herein are fatty acid carbohydrate-hydroxyl-hybrid compounds and derivatives thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions thereof.

US Patent:

20130156813, Jun 20, 2013

Filed:

Aug 5, 2011

Appl. No.:

13/814337

Inventors:

Jeffrey Gildersleeve - Frederick MD, US
Christopher Campbell - Baltimore MD, US
Oyindasola Oyelaran - Boston MA, US
James Gulley - Takoma Park MD, US
Jeffrey Schlom - Potomac MD, US

International Classification:

A61K 39/00

US Classification:

4242771, 435 792, 536 111, 530395

Abstract:

The invention provides a method for predicting the clinical response to a cancer vaccine in a patient having cancer, a method for determining the immune response to a cancer vaccine in a patient having cancer who has been administered a cancer vaccine, a method for determining the long-term survival in a patient having cancer, corresponding kits therefor, as well as methods of for improving the efficacy of a virus-based vaccine.

US Patent:

20220381780, Dec 1, 2022

Filed:

May 20, 2022

Appl. No.:

17/749721

Inventors:

- Rockville MD, US
James WILBUR - Germantown MD, US
Jeffery DEBAD - Ijamsville MD, US
Hans BIEBUYCK - Potomac MD, US
Priscilla KRAI - Germantown MD, US
Alan KISHBAUGH - Rockville MD, US
Leonid DZANTIEV - Ellicott City MD, US
Christopher SHELBURNE - Rockville MD, US
Christopher CAMPBELL - Columbia MD, US
Anastasia AKSYUK - Rockville MD, US
Adrian MCDERMOTT - Bethesda MD, US
Sarah O'CONNELL - Bethesda MD, US
Sandeep NARPALA - Bethesda MD, US
Chien Li LIN - Gaithersburg MD, US

International Classification:

G01N 33/569
G01N 33/543
G01N 33/58

Abstract:

The invention relates to methods and kits for determining a SARS-CoV-2 strain in a sample. The invention further provides methods and kits for detecting a single nucleotide polymorphism (SNP) in a target nucleic acid, wherein the target nucleic acid is a SARS-CoV-2 nucleic acid. The invention further provides methods and kits for detecting one or more antibody biomarkers in a sample.

US Patent:

20230021837, Jan 26, 2023

Filed:

Nov 25, 2020

Appl. No.:

17/779900

Inventors:

- Rockville MD, US
Mingyue WANG - Potomac MD, US
Christopher CAMPBELL - Columbia MD, US
Katarzyna HAYNESWORTH - Buckeystown MD, US
Nikhil PADMANABHAN - McLean VA, US
Martin STENGELIN - Gaithersburg MD, US
Paridhi GUPTA - Boyds MD, US
Rashmi SRIRAM - Gaithersburg MD, US

International Classification:

G01N 33/564
G01N 33/543

Abstract:

The invention relates to assay methods and kits for assessing autoimmune diseases in a human subject. In embodiments, the present disclosure provides assay methods and kits for diagnosing a subject with or predicting that a subject will develop Type 1 diabetes. In embodiments, the present disclosure provides assay methods and kits for assessing responsiveness of a subject having Type 1 diabetes to treatment with alefacept. In embodiments, the present disclosure provides assay methods and kits for diagnosing a subject with systemic lupus erythematosus. In embodiments, the present disclosure provides assay methods and kits for determining if a subject is at risk of a systemic lupus erythematosus flare. In embodiments, the present disclosure provides assay methods and kits for diagnosing a subject with celiac disease.

US Patent:

20210349104, Nov 11, 2021

Filed:

Apr 30, 2021

Appl. No.:

17/246364

Inventors:

- Rockville MD, US
Anu MATHEW - North Potomac MD, US
James WILBUR - Germantown MD, US
Jeffery DEBAD - Ijamsville MD, US
Christopher CAMPBELL - Columbia MD, US
Hans BIEBUYCK - Potomac MD, US
Priscilla KRAI - Germantown MD, US
Alan KISHBAUGH - Rockville MD, US
Leonid DZANTIEV - Ellicott City MD, US
Christopher SHELBURNE - Rockville MD, US
Pu LIU - Rockville MD, US
Paul GOODWIN - Frederick MD, US
Adrian MCDERMOTT - Bethesda MD, US
Sarah O'CONNELL - Bethesda MD, US
Sandeep NARPALA - Bethesda MD, US

International Classification:

G01N 33/68

Abstract:

The invention relates to methods and kits for detecting a virus, e.g., a respiratory virus such as a coronavirus, in a biological sample. The invention also relates to methods and kits for detecting and/or quantifying biomarkers, e.g., antibody biomarkers against a viral antigen; inflammatory and/or tissue damage response biomarkers; and/or extracellular vesicles in response to a viral infection.

US Patent:

20170052185, Feb 23, 2017

Filed:

Nov 8, 2016

Appl. No.:

15/345634

Inventors:

- Bethesda MD, US
Christopher Campbell - Baltimore MD, US
Oyindasola Oyelaran - Boston MA, US
James Gulley - Takoma Park MD, US
Jeffrey Schlom - Potomac MD, US

Assignee:

The United States of America, as represented by the Secretary, Department of Health and Human Serv - Bethesda MD

International Classification:

G01N 33/574
A61K 39/00

Abstract:

The invention provides a method for predicting the clinical response to a cancer vaccine in a patient having cancer, a method for determining the immune response to a cancer vaccine in a patient having cancer who has been administered a cancer vaccine, a method for determining the long-term survival in a patient having cancer, corresponding kits therefor, as well as methods of for improving the efficacy of a virus-based vaccine.